Aileron Therapeutics to Present at the Canaccord Genuity 38th Annual Growth Conference
August 02 2018 - 7:00AM
Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of
stapled peptide therapeutics for cancers and other diseases, today
announced that Manuel Aivado, SVP and Chief Medical Officer, will
present at the Canaccord Genuity 38th Annual Growth Conference
being held in Boston, MA.
Presentation Details:
Event: Canaccord Genuity 38th
Annual Growth Conference |
Date: Thursday, August
9, 2018 |
Time: 1:00 – 1:25 p.m.
EDT |
Location: Intercontinental Boston Hotel,
Boston, MA |
A live webcast of the presentation may be accessed from the
Events & Presentations section of Aileron’s website. An
archived version of the webcast will be available for replay
following the event.
About Aileron Aileron is a clinical-stage
biopharmaceutical company advancing stapled peptides, a novel class
of therapeutics for cancers and other diseases. Stapled peptides
are chemically stabilized alpha-helical peptides that are modified
to improve their stability and cell penetrability while maintaining
high affinity for large protein surfaces. Our goal is to use our
proprietary stapled peptide drug platform to create first-in-class
therapeutics, like ALRN-6924, that may be able to address
historically undruggable targets and complex mechanisms that
underlie many diseases with high unmet medical need. Our platform
enables us to chemically stabilize and improve the performance and
activity of a broad range of alpha-helical peptides that we believe
can potentially activate and inhibit key cellular functions that
are otherwise difficult to target with existing drug technologies,
including small molecules and monoclonal antibodies. For more
information, visit www.aileronrx.com.
About ALRN-6924 ALRN-6924 is a first-in-class
product candidate designed to reactivate wild type p53 tumor
suppression by disrupting the interactions between p53 and the two
primary p53 suppressor proteins, MDMX and MDM2. Aileron believes
ALRN-6924 is the first and only product candidate in clinical
development that can equipotently bind to and disrupt the
interaction of MDMX and MDM2 with p53. Based on preclinical data
and preliminary evidence of safety and anti-tumor activity in its
ongoing clinical trials, there may be a significant opportunity to
develop ALRN-6924 as a monotherapy or combination therapy for a
wide variety of solid and liquid tumors. ALRN-6924 is currently
being evaluated in multiple clinical trials for the treatment of
acute myeloid leukemia (AML), advanced myelodysplastic syndrome
(MDS) and peripheral T-cell lymphoma (PTCL). For information about
its clinical trials, please visit www.clinicaltrials.gov.
Source: Aileron Therapeutics
Investors:
Aileron Therapeutics
Don Dougherty, CFO
617-995-0900
ddougherty@aileronrx.com
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Jul 2023 to Jul 2024